Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;30(15):2400563.
doi: 10.2807/1560-7917.ES.2025.30.15.2400563.

Prevalence and risk factors for carriage of carbapenem-resistant Acinetobacter baumannii in post-acute care hospitals, Israel, 2021

Vered Schechner  1   2 , Samira Masarwa  2 , Gabrielle D Levi  2 , Adi Cohen  2 , Fadi Assi  2 , Moshe Bechor  2 , Elizabeth Temkin  2 , Alona Keren-Paz  2 , Mitchell J Schwaber  1   2 , Yehuda Carmeli  1   2 ; Israel PACH CRAB Working Group  3 ; PACH working group
Collaborators, Affiliations

Prevalence and risk factors for carriage of carbapenem-resistant Acinetobacter baumannii in post-acute care hospitals, Israel, 2021

Vered Schechner et al. Euro Surveill. 2025 Apr.

Abstract

BackgroundPost-acute care hospitals (PACH) may act as regional reservoirs for multidrug-resistant organisms.AimWe aimed to investigate the prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) carriers and identify risk factors for CRAB carriage in PACH.MethodsWe conducted a point prevalence survey in 18 PACH in Israel from June to December 2021. We screened patients in 55 wards of four types (mechanical ventilation, skilled nursing, sub-acute and rehabilitation) for CRAB carriage from skin, rectum and tracheostomy secretions (if applicable). We collected data on patient characteristics (including prior CRAB carriage) and ward and institution characteristics. We calculated the prevalence of CRAB carriers, the percentage of newly detected carriers, and assessed predictors of CRAB carriage using a mixed-effects logistic regression model.ResultsWe screened 1,725 patients, with 385 (22%) testing positive for CRAB. The median prevalence of CRAB carriers was 48% (interquartile range (IQR): 33-70) in ventilation wards, 28% (IQR: 18-46) in skilled nursing wards, 8% (IQR: 6-13) in sub-acute wards and 0% (IQR: 0-3) in rehabilitation wards. Only 31% (118/385) had a known history of CRAB carriage. Individual risk factors for CRAB positivity included known CRAB carriage, bedsores and presence of a feeding tube. Modifiable ward-level risk factors included poor availability of alcohol-based hand rub (adjusted odds ratio (aOR) = 3.22; 95% confidence interval (CI): 1.52-6.81) and suctioning in common areas (aOR = 2.23; 95% CI: 1.30-3.85).ConclusionsThe hidden reservoir of CRAB carriers in Israeli ventilation and skilled nursing wards is large. We identified modifiable risk factors at ward level, highlighting areas for targeted intervention.

Keywords: antibiotic resistance; carbapenem-resistant Acinetobacter baumannii; infection control; point prevalence survey; post-acute care hospitals.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Yehuda Carmeli has received grants and personal fees from Pfizer, Roche, Qpex Pharmaceuticals, and Enlivex Therapeutics. All other authors have no conflicts of interest.

Figures

Figure
Figure
Carbapenem-resistant Acinetobacter baumannii prevalence in post-acute care hospitals, by ward type, Israel, 2021 (n = 1,725)
See this image and copyright information in PMC

References

    1. Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019;8(1):1747-59. 10.1080/22221751.2019.1698273 - DOI - PMC - PubMed
    1. Kempf M, Rolain J-M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012;39(2):105-14. 10.1016/j.ijantimicag.2011.10.004 - DOI - PubMed
    1. Russo A, Bassetti M, Ceccarelli G, Carannante N, Losito AR, Bartoletti M, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130-8. 10.1016/j.jinf.2019.05.017 - DOI - PubMed
    1. Munoz-Price LS, Arheart K, Nordmann P, Boulanger AE, Cleary T, Alvarez R, et al. Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit Care Med. 2013;41(12):2733-42. 10.1097/CCM.0b013e318298a541 - DOI - PubMed
    1. Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions. Clin Infect Dis. 2024;78(2):248-58. 10.1093/cid/ciad556 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources